estrone has been researched along with rosiglitazone in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barkhem, T; Beno, DW; Cherrington, A; Edgerton, DS; Efendic, S; Fey, T; Fung, S; Goos-Nilsson, A; Grynfarb, M; Jacobson, PB; Kym, PR; Lane, BC; Link, JT; Marsh, K; Mika, A; Nga-Nguyen, B; Nguyen, PT; Ohman, L; Opgenorth, TJ; Osterland, M; Tu, N; von Geldern, TW; Wang, J; Wilcox, D; Zinker, B | 1 |
| Bayraktar, F; Dereli, D; Dereli, T; Ozgen, AG; Yilmaz, C | 1 |
| Bahtiyar, G; Sacerdote, AS; Weiss, K | 1 |
| Alemany, M; Cabot, C; Fernández-López, JA; Ferrer-Lorente, R | 1 |
| Araki, T; Avtanski, D; Parikh, G; Poretsky, L; Rosenwaks, Z; Seto-Young, D; Strizhevsky, M; Suwandhi, P | 1 |
1 review(s) available for estrone and rosiglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for estrone and rosiglitazone
| Article | Year |
|---|---|
Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease.
Topics: Adult; Androstenedione; Blood Glucose; Body Mass Index; Dose-Response Relationship, Drug; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Glycated Hemoglobin; Hirsutism; Humans; Hypoglycemic Agents; Insulin; Luteinizing Hormone; Ovulation; Polycystic Ovary Syndrome; Rosiglitazone; Testosterone; Thiazolidinediones | 2005 |
8 other study(ies) available for estrone and rosiglitazone
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.
Topics: 3T3 Cells; Adipocytes; Animals; Biotransformation; Blood Glucose; Cell Differentiation; Cholic Acids; Diabetes Mellitus, Type 2; Dogs; Drug Synergism; Estrone; Glucocorticoids; Glucose; Glutamate-Ammonia Ligase; Hypoglycemic Agents; Liver; Male; Mice; Obesity; Prednisolone; Rats; Rats, Zucker; Receptors, Glucocorticoid; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Tyrosine Transaminase | 2005 |
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adult; Aged; Antipsychotic Agents; Cortodoxone; Dehydroepiandrosterone; Endocrine Disruptors; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Male; Metformin; Middle Aged; Radioimmunoassay; Rosiglitazone; Testosterone; Thiazolidinediones; Valproic Acid | 2007 |
Site-specific modulation of white adipose tissue lipid metabolism by oleoyl-estrone and/or rosiglitazone in overweight rats.
Topics: Adipose Tissue, White; Animals; Anti-Obesity Agents; Body Composition; Drug Interactions; Estrone; Hypoglycemic Agents; Lipid Metabolism; Lipogenesis; Lipolysis; Lipoprotein Lipase; Male; Oleic Acids; Overweight; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Wistar; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones | 2010 |
Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase.
Topics: Androgens; Aromatase; Cells, Cultured; Down-Regulation; Estrogens; Estrone; Female; Granulosa Cells; Humans; Pioglitazone; Protein Binding; Rosiglitazone; Thiazolidinediones | 2011 |